The prevalence of fungal infections and onychomycosis in the population determines the relevance of entering the Ukrainian market of a new antifungal drug terbinafine – TERBINORMA in the form of tablets. TERBINORM is used to treat fungal infections of the skin and nails caused by dermatophytes Trichophyton, Microsportum and Epidermophyton, dermatophytosis lesions of the smooth skin of the trunk, perineum and feet, when the localization of the lesion, the severity or prevalence of the infection.
The effectiveness of the clinical action of TERBINORMA is determined by terbinafine in its composition, which:
- is active against dermatophytes, molds and yeast fungi;
- has a fungicidal effect in low concentrations;
- provides high efficiency of antimycotic therapy (Trivedi N.A., Shah P.C., 2010; Belozorov A.P., 2008; Kalyuzhnaya L.D., 2013);
- causes a low recurrence rate against the background of antimycotic therapy (Yin Z. et al., 2011; Kalyuzhnaya L.D., 2013; Vora D.N. et al., 2014).